"Tiotropium Bromide" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A scopolamine derivative and CHOLINERGIC ANTAGONIST that functions as a BRONCHODILATOR AGENT. It is used in the treatment of CHRONIC OBSTRUCTIVE PULMONARY DISEASE.
| Descriptor ID |
D000069447
|
| MeSH Number(s) |
D02.145.074.722.822.887 D03.132.889.601.887 D03.605.084.500.722.822.887 D03.605.869.822.887
|
| Concept/Terms |
Tiotropium Bromide- Tiotropium Bromide
- Bromide, Tiotropium
- 7-((hydroxybis(2-thienyl)acetyl)oxy)-9,9-dimethyl-3-oxa-9-azoniatricyclo(3.3.1.0(2,4))nonane bromide
BA 679 BR- BA 679 BR
- 679 BR, BA
- BR, BA 679
- BA-679 BR
- BA679 BR
|
Below are MeSH descriptors whose meaning is more general than "Tiotropium Bromide".
Below are MeSH descriptors whose meaning is more specific than "Tiotropium Bromide".
This graph shows the total number of publications written about "Tiotropium Bromide" by people in this website by year, and whether "Tiotropium Bromide" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2007 | 0 | 1 | 1 |
| 2008 | 0 | 1 | 1 |
| 2009 | 0 | 3 | 3 |
| 2011 | 0 | 3 | 3 |
| 2013 | 0 | 1 | 1 |
| 2017 | 1 | 0 | 1 |
| 2020 | 0 | 1 | 1 |
| 2023 | 0 | 1 | 1 |
| 2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Tiotropium Bromide" by people in Profiles.
-
Cardiovascular Events with the Use of Long-Acting Muscarinic Receptor Antagonists: An Analysis of the FAERS Database 2020-2023. Lung. 2024 04; 202(2):119-125.
-
Adding tiotropium or long-acting ?2-agonists to inhaled corticosteroids: Asthma-related exacerbation risk and healthcare resource utilization. Allergy Asthma Proc. 2023 11 13; 44(6):413-421.
-
Dual-combination maintenance inhaler preferences in asthma and chronic obstructive pulmonary disease: A patient-centered benefit-risk assessment. Respir Med. 2021 01; 176:106278.
-
Long-term safety and efficacy of glycopyrrolate/formoterol metered dose inhaler using novel Co-Suspension? Delivery Technology in patients with chronic obstructive pulmonary disease. Respir Med. 2017 05; 126:105-115.
-
Ten years of tiotropium: clinical impact and patient perspectives. Int J Chron Obstruct Pulmon Dis. 2013; 8:117-25.
-
Benefits of adding fluticasone propionate/salmeterol to tiotropium in moderate to severe COPD. Respir Med. 2012 Jan; 106(1):91-101.
-
Blinded 12-week comparison of once-daily indacaterol and tiotropium in COPD. Eur Respir J. 2011 Oct; 38(4):797-803.
-
Acute bronchodilator responsiveness and health outcomes in COPD patients in the UPLIFT trial. Respir Res. 2011 Jan 11; 12:6.
-
Nebulized formoterol provides added benefits to tiotropium treatment in chronic obstructive pulmonary disease. Adv Ther. 2009 Nov; 26(11):1024-34.
-
Therapeutic conversion of the combination of ipratropium and albuterol to tiotropium in patients with chronic obstructive pulmonary disease. Pulm Pharmacol Ther. 2009 Dec; 22(6):587-92.